Transaction Update & Notice of Intention to Delist

AI SummaryClose X

Roquefort Therapeutics plc is proceeding with a significant transaction involving the acquisition of worldwide exclusive rights to AO-252, a cancer drug candidate targeting TACC3, from Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc. This acquisition is contingent upon the company's shares being admitted to the AIM market of the London Stock Exchange. Concurrently, Roquefort Therapeutics intends to delist its ordinary shares from the Main Market of the London Stock Exchange, with the delisting expected to become effective in at least 20 business days. Documentation for the associated equity fundraise, the AIM Admission Document, and a Notice of General Meeting are being finalized and are expected to be published shortly.

Disclaimer*

UK 100

Latest directors dealings